Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

Al­to Neu­ro­science bags $25M for four Phase II drugs

An­oth­er $25 mil­lion is flow­ing the way of a Cal­i­for­nia biotech at­tempt­ing to fix the “tri­al and er­ror” sys­tem in neu­ro­science drug R&D.

Al­to Neu­ro­science picked up the cap­i­tal from Al­pha Wave Ven­tures via an ex­ten­sion to its Se­ries B, bring­ing to­tal eq­ui­ty raised to $100 mil­lion since the start­up’s 2019 found­ing. The biotech al­so re­cent­ly signed up for a $35 mil­lion cred­it fa­cil­i­ty.

All that cap­i­tal will help the biotech in­ves­ti­gate four drugs through four Phase II read­outs, Al­to said Mon­day morn­ing. That means enough mon­ey to keep the lights on in­to 2025, a year longer than pro­ject­ed un­der the orig­i­nal Se­ries B close.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.